News and Updates
Starting the Year at JPM Healthcare Week
JPM Healthcare Week has kicked off! Reglagene's CEO Richard Austin is participating in the Biotech Showcase and BIO Partnering. Reach out if you'd like to discuss our brain penetrant cancer therapy!
Concluding 2024 in Houston, Texas
2024 has been a big year for Reglagene. We are pleased to have expanded to our new office in Houston, Texas.
Brain Tumour Research Novel Therapeutics Accelerator
We’re thrilled to share that Reglagene was selected to participate in the Brain Tumour Research Novel Therapeutics Accelerator on November 6th in Boston!
Texas Life Science Forum Presentation
With almost 700 attendees at the Texas Life Science forum, it was an honor to have the opportunity to be a presenting company! Many thanks to Ann Tanabe with BioHouston and Brad Burke with Rice Alliance for Technology and Entrepreneurship for putting together a top tier event!
IC3 Life Science Summit Presentation
Earlier this month, our CEO, Richard Austin, delivered a powerful pitch at the IC3 Life Science Summit in Dallas, showcasing our mission to redefine brain cancer treatment. A huge thank you to BioNTX for hosting an incredible event and for bringing together visionary leaders in life sciences.
Arizona White Hat Conference
Thank you, Arizona! Last month, Reglagene’s CEO Richard Austin had the privilege of presenting at Arizona BioIndustry Association (AZBio)’s White Hat Conference, and we couldn’t be more grateful.
The Rocky Mountain Life Sciences Investor & Partnering Conference
Grateful to have participated in the Rocky Mountain Life Sciences Investor and Partnering Conference in Breckenridge, Colorado! The Reglagene team had valuable conversations with industry leaders and investors, and CEO Richard Austin shared exciting updates on our lead asset in preclinical development. We're energized by the momentum and eager for what's next!
Presentation at BioCentury, in Nashville
Thank you, BioCentury Inc., Nashville! The Reglagene team had a great three days engaging in insightful discussions with key stakeholders and industry leaders. CEO Richard Austin took the stage to share exciting updates on our lead asset currently in preclinical development.
Welcoming Ben Maurey as a Commercial Advisor
We are excited to welcome Ben Maurey to Reglagene as our commercial-focused advisor on our Advisory Board. Ben comes to Reglagene after 8 years in the oncology space with a wide variety of roles and responsibilities.